LNP-Delivered CRISPR Slashes Lipids
Phase 1 data shows that an LNP-delivered CRISPR therapy achieved significant reductions in cholesterol and triglycerides, with LDL lowered by 50% and TG by 55%. The results underscore the growing importance of LNP delivery capacity and robust CMC and analytical capabilities as key differentiators in the gene editing space.
The therapy, CTX310 from CRISPR Therapeutics, targets the *ANGPTL3* gene in the liver. This gene is a known regulator of lipid metabolism; individuals with natural loss-of-function mutations in *ANGPTL3* exhibit lifelong low cholesterol and triglyceride levels and a reduced risk of cardiovascular disease. The one-time intravenous infusion uses a lipid nanoparticle (LNP) to deliver the Cas9 gene-editing machinery to hepatocytes. Data from the Phase 1 trial, which enrolled 15 patients, showed dose-dependent reductions in circulating ANGPTL3 protein, with a mean reduction of 73% at the highest dose. This led to maximal reductions of up to 87% for LDL and 84% for triglycerides. The lipid-lowering effects were observed within two weeks and were sustained for at least 60 days of follow-up. The safety profile was generally favorable, with no serious adverse events related to the treatment. Some participants experienced minor, resolvable infusion-related reactions like back pain and nausea. This early safety data is crucial as the FDA typically recommends up to 15 years of long-term safety monitoring for CRISPR-based therapies. This *in vivo* LNP-based approach contrasts with *ex vivo* cell therapies, simplifying the manufacturing and delivery process into a single-infusion product. For CDMOs, this shifts the biomanufacturing focus from complex cell handling to the scalable production of LNPs and their nucleic acid payloads, demanding robust analytical capabilities to ensure consistency and quality of the final product. The success of LNP delivery for this and other programs, such as Verve Therapeutics' PCSK9-targeting base editor, highlights a critical industry trend. As more *in vivo* gene editing therapies advance, the ability to manufacture LNPs at scale with precise control over particle size, charge, and encapsulation efficiency becomes a key competitive differentiator and a core value proposition for specialized CDMOs. Targeting *ANGPTL3* is a validated strategy, with other modalities like monoclonal antibodies and antisense oligonucleotides also in development, though they require repeat dosing. The potential for a "one-and-done" treatment that provides durable, lifelong lipid reduction could fundamentally alter the management of atherosclerotic cardiovascular disease, a major driver for innovation in bioprocess development for curative therapies.
